Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/43886

TitleTherapeutic l-asparaginase: upstream, downstream and beyond
Author(s)Lopes, Andre Moreni
Oliveira-Nascimento, Laura de
Ribeiro, Artur
Tairum Jr, Carlos Abrunhosa
Breyer, Carlos Alexandre
Oliveira, Marcos Antonio de
Monteiro, Gisele
Souza-Motta, Cristina Maria de
Magalhães, Pérola de Oliveira
Avendaño, Jorge Gonzalo Farías
Cavaco-Paulo, Artur
Mazzola, Priscila Gava
Rangel-Yagui, Carlota de Oliveira
Sette, Lara Durães
Converti, Attilio
Pessoa, Adalberto
KeywordsAcute lymphoblastic leukemia
antineoplastic activity
biopharmaceutical
l-asparaginase
microbial l-asparaginase production
Issue date2017
PublisherInforma Healthcare
JournalCritical Reviews in Biotechnology
CitationLopes, Andre Moreni; Oliveira-Nascimento, Laura de; Ribeiro, Artur; Tairum Jr, Carlos Abrunhosa; Breyer, Carlos Alexandre; Oliveira, Marcos Antonio de; Monteiro, Gisele; Souza-Motta, Cristina Maria de; Magalhães, Pérola de Oliveira; Avendaño, Jorge Gonzalo Farías; Cavaco-Paulo, Artur; Mazzola, Priscila Gava; Rangel-Yagui, Carlota de Oliveira; Sette, Lara Durães; Converti, Attilio; Pessoa, Adalberto, Therapeutic l-asparaginase: upstream, downstream and beyond. Critical Reviews in Biotechnology, 37(1), 82-99, 2017
Abstract(s)L-asparaginase (L-asparagine amino hydrolase, E.C.3.5.1.1) is an enzyme clinically accepted as an antitumor agent to treat acute lymphoblastic leukemia and lymphosarcoma. It catalyzes L-asparagine (Asn) hydrolysis to L-aspartate and ammonia, and Asn effective depletion results in cytotoxicity to leukemic cells. Microbial L-asparaginase (ASNase) production has attracted considerable attention owing to its cost effectiveness and eco-friendliness. The focus of this review is to provide a thorough review on microbial ASNase production, with special emphasis to microbial producers, conditions of enzyme production, protein engineering, downstream processes, biochemical characteristics, enzyme stability, bioavailability, toxicity and allergy potential. Some issues are also highlighted that will have to be addressed to achieve better therapeutic results and less side effects of ASNase use in cancer treatment: (a) search for new sources of this enzyme to increase its availability as a drug; (b) production of new ASNases with improved pharmacodynamics, pharmacokinetics and toxicological profiles, and (c) improvement of ASNase production by recombinant microorganisms. In this regard, rational protein engineering, directed mutagenesis, metabolic flux analysis and optimization of purification protocols are expected to play a paramount role in the near future.
TypeArticle
URIhttp://hdl.handle.net/1822/43886
DOI10.3109/07388551.2015.1120705
ISSN0738-8551
e-ISSN1549-7801
Publisher versionhttp://informahealthcare.com/journal/bty
Peer-Reviewedyes
AccessRestricted access (UMinho)
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_30706_1.pdf
  Restricted access
1,78 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID